CN112156176A - 治疗脑内出血的组合物和方法 - Google Patents

治疗脑内出血的组合物和方法 Download PDF

Info

Publication number
CN112156176A
CN112156176A CN202011260045.4A CN202011260045A CN112156176A CN 112156176 A CN112156176 A CN 112156176A CN 202011260045 A CN202011260045 A CN 202011260045A CN 112156176 A CN112156176 A CN 112156176A
Authority
CN
China
Prior art keywords
ich
less
fxa
hours
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011260045.4A
Other languages
English (en)
Chinese (zh)
Inventor
S·阿金
J·弗鲁比斯
M·E·卡尔
S·赫特
R·贾舒亚
D·D·彼德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN112156176A publication Critical patent/CN112156176A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202011260045.4A 2014-01-24 2015-01-15 治疗脑内出血的组合物和方法 Pending CN112156176A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931071P 2014-01-24 2014-01-24
US61/931,071 2014-01-24
CN201580005696.XA CN105934250A (zh) 2014-01-24 2015-01-15 治疗脑内出血的组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580005696.XA Division CN105934250A (zh) 2014-01-24 2015-01-15 治疗脑内出血的组合物和方法

Publications (1)

Publication Number Publication Date
CN112156176A true CN112156176A (zh) 2021-01-01

Family

ID=52630418

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011260045.4A Pending CN112156176A (zh) 2014-01-24 2015-01-15 治疗脑内出血的组合物和方法
CN201580005696.XA Pending CN105934250A (zh) 2014-01-24 2015-01-15 治疗脑内出血的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580005696.XA Pending CN105934250A (zh) 2014-01-24 2015-01-15 治疗脑内出血的组合物和方法

Country Status (18)

Country Link
US (2) US20160375109A1 (enExample)
EP (1) EP3096779B1 (enExample)
JP (1) JP6624787B2 (enExample)
KR (3) KR20180014221A (enExample)
CN (2) CN112156176A (enExample)
AU (1) AU2015208819B2 (enExample)
BR (1) BR112016014617A2 (enExample)
CA (1) CA2937418A1 (enExample)
DK (1) DK3096779T3 (enExample)
ES (1) ES2772802T3 (enExample)
HU (1) HUE047588T4 (enExample)
IL (1) IL246637A0 (enExample)
MX (1) MX375355B (enExample)
PL (1) PL3096779T3 (enExample)
PT (1) PT3096779T (enExample)
RU (1) RU2016126423A (enExample)
SI (1) SI3096779T1 (enExample)
WO (1) WO2015110939A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2761730T3 (es) * 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
EP3049434A1 (en) 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101356192A (zh) * 2005-11-15 2009-01-28 费城儿童医院 用于调节止血的组合物和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123118A1 (en) * 2004-06-21 2005-12-29 Novo Nordisk Health Care Ag Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich)
JP2011509978A (ja) * 2008-01-18 2011-03-31 ノボ ノルディスク ヘルス ケア アーゲー 選択されたＩＣＨ患者亜集団における脳内出血（ＩＣＨ）後の出血拡大、及び／又は浮腫生成の予防又は減弱のための、第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
ES2605801T3 (es) * 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
WO2011020866A2 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US9371522B2 (en) * 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
WO2014018120A1 (en) * 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
ES2761730T3 (es) * 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101356192A (zh) * 2005-11-15 2009-01-28 费城儿童医院 用于调节止血的组合物和方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERIC SANDLER等: "Prevention of Recurrent Intracranial Hemorrhage in a Factor X-Deficient Infant", 《THE AMERICAN JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY》, vol. 14, no. 2, pages 163 - 165 *
LACRAMIOARA IVANCIU等: "A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia", 《NATURE BIOTECHNOLOGY》, vol. 29, no. 11, pages 1028 - 1035 *

Also Published As

Publication number Publication date
EP3096779B1 (en) 2019-12-18
US20190231856A1 (en) 2019-08-01
RU2016126423A (ru) 2018-03-01
AU2015208819B2 (en) 2020-01-23
ES2772802T3 (es) 2020-07-08
MX2016009665A (es) 2016-11-14
CA2937418A1 (en) 2015-07-30
JP2015147764A (ja) 2015-08-20
HUE047588T4 (hu) 2020-06-29
EP3096779A1 (en) 2016-11-30
US20160375109A1 (en) 2016-12-29
IL246637A0 (en) 2016-08-31
DK3096779T3 (da) 2020-02-24
AU2015208819A1 (en) 2016-06-30
WO2015110939A1 (en) 2015-07-30
KR20160093731A (ko) 2016-08-08
MX375355B (es) 2025-03-04
KR20210008177A (ko) 2021-01-20
PL3096779T3 (pl) 2020-05-18
BR112016014617A2 (pt) 2017-09-19
SI3096779T1 (sl) 2020-03-31
KR20180014221A (ko) 2018-02-07
RU2016126423A3 (enExample) 2018-03-01
JP6624787B2 (ja) 2019-12-25
HUE047588T2 (hu) 2020-04-28
CN105934250A (zh) 2016-09-07
PT3096779T (pt) 2020-02-21

Similar Documents

Publication Publication Date Title
JP6437458B2 (ja) 第Ｘａ因子の阻害を中和するための組成物および方法
TW200817033A (en) Method of treating stroke with thrombolytic agent
IL256243A (en) Methods and preparations for treating conditions related to aging
JP6846063B2 (ja) 異常な皮膚瘢痕化の治療
CN114259558A (zh) Adamts13的皮下施用
JP2020502150A (ja) グルカゴン、インスリンを正常なバランスに戻らせる方法
AU2019272030A1 (en) Promoting epithelial regeneration post tonsillectomy using heparin binding epidermal growth factor like growth factor
KR20220127880A (ko) 신경 손상 및 이의 관련 병증 치료 방법
CN113795274A (zh) 一种治疗肌萎缩侧索硬化的方法和药物
US20190231856A1 (en) Compositions and methods for treating intracerebral hemorrhage
HK40040435A (en) Compositions and methods for treating intracerebral hemorrhage
JP2022519327A (ja) 頭蓋内出血の治療方法及び効果の評価方法
CN119909180A (zh) 一种治疗肌萎缩侧索硬化的方法和药物
EP3420087B1 (en) Peptide-based methods for treating neurological injury
JP6629744B2 (ja) 第Ｘａ因子の半減期を延ばす組成物および方法
HK1228257A1 (en) Compositions and methods for treating intracerebral hemorrhage
HK1257596A1 (zh) 一种促进胰岛素分泌的方法
JP2021138699A (ja) 梗塞における閉塞した血管の再疎通のための方法で使用するためのａｄａｍｔｓ１３を含む組成物
RU2818474C2 (ru) Гаптоглобин для применения в лечении неблагоприятного вторичного неврологического исхода после геморрагического инсульта
JP2009501188A (ja) 抗血小板療法で治療される患者における脳内出血（ＩＣＨ）後の出血増大及び／又は浮腫形成を予防又は軽減するための第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
WO2026076443A1 (en) Methods for treating factor x deficiency
JPWO2020084853A1 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
HK1240123A1 (en) Method for preventing or treating liver damage and associated diseases
HK1240124A1 (en) Method for preventing or treating diabetic nerve injury and related diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40040435

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210101